INVESTORS CONTACT US ABOUT US OUR SCIENCE OUR PIPELINE RESOURCES JOIN US OUR VISION Armed with a novel approach for resolving inflammation and expertise ranging from drug discovery through FDA approval, we merge future-focused intention with data-driven innovation. We have earned our reputation by developing Vyleesi® (bremelanotide injection), a novel treatment for women with generalized hypoactive sexual desire disorder (HSDD). We are determined to leverage our unique insight into the industry and the melanocortin system to develop groundbreaking therapeutics for inflammatory and autoimmune diseases, with a focus on ocular conditions. DOWNLOAD OUR CORPORATE PRESENTATION LEADERSHIP Our management exemplifies the powerful combination of science and business. We support a fast-paced, efficient, nimble, and collaborative working environment that focuses on developing innovative treatments that work with the melanocortin system. Carl Spana, PhD Chief Executive Officer, President, and Director Stephen T. Wills, CPA, MST Chief Financial Officer, Chief Operating Officer, and Treasurer and Secretary Stephen Slusher Chief Legal Officer Michael Raizman, MD Chief Medical Officer John Dodd, PhD Senior Vice President, Preclinical Development James Hattersley Senior Vice President, Business Development Robert Jordan Senior Vice President, Program Operations Paul Kayne, PhD Vice President, Biological Sciences Nicole Pederson, MS Executive Director, Quality Assurance Samrat Sisodia, PhD Executive Director, Regulatory Affairs J. Don Wang, PhD VP, Product Development BOARD OF DIRECTORS Carl Spana, PhD Chief Executive Officer, President and Director John K.A. Prendergast, PhD Director, Chairman of the Board of Directors Robert K. deVeer, Jr Director J. Stanley Hull Director Alan W. Dunton, MD Director Arlene M. Morris Director Anthony M. Manning, PhD Director SCIENTIFIC ADVISORY BOARD Palatin works with leading experts who help shape our research and advise on our clinical development programs. CORPORATE GOVERNANCE The Board of Directors of Palatin sets high standards for its employees, officers, and directors. The Board of Directors oversees the management of Palatin and follows the procedures and standards set forth in the guidelines below. The Board of Directors modifies these guidelines from time to time as it determines is in the best interests of Palatin or as required by applicable laws and regulations. Nominating and Corporate Governance Committee Charter Audit Committee Charter Compensation Committee Charter Code of Corporate Conduct and Ethics Clawback Policy Minimum Share Ownership Guidelines for Directors and Certain Officers REPORTING HOTLINE Palatin maintains a Reporting Hotline for reporting suspected violations of our Code of Corporate Conduct and Ethics. REPORTING HOTLINE 4-B Cedar Brook Drive Cedar Brook Corporate Center Cranbury, NJ 08512 © 2021 PALATIN | ALL RIGHTS RESERVED | PRIVACY POLICY | TERMS OF USE | ACCESSIBILITY STATEMENT